WallStreetZenWallStreetZen

NASDAQ: MYGN
Myriad Genetics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MYGN past revenue growth

How has MYGN's revenue growth performed historically?
Company
-1.77%
Industry
10.63%
Market
21.8%
MYGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MYGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MYGN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MYGN earnings and revenue history

Current Revenue
$678.4M
Current Earnings
-$112.0M
Current Profit Margin
-16.5%

MYGN Return on Equity

Current Company
-12.1%
Current Industry
421.7%
Current Market
188.7%
MYGN's Return on Equity (-12.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MYGN announces earnings.

MYGN Return on Assets

Current Company
-9.2%
Current Industry
6.6%
MYGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MYGN Return on Capital Employed

Current Company
-12.94%
Current Industry
10.9%
MYGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MYGN vs Diagnostic & Research Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MYGN$678.40M-$73.00M-$112.00M-1.22%N/A
PACB$128.30M-$282.24M-$314.25M+6.54%N/A
NEO$509.73M-$78.63M-$144.25M+16.23%N/A
RDNT$1.43B$255.58M$10.65M+9.17%-27.03%
OLK$139.85M$2.45M-$12.85M+133.03%N/A
View Top Diagnostic & Research Stocks

MYGN earnings dates

Next earnings date
May 3, 2023

Myriad Genetics Earnings & Revenue FAQ

What were MYGN's earnings last quarter?

On Invalid Date, Myriad Genetics (NASDAQ: MYGN) reported Q4 2022 earnings per share (EPS) of -$0.52, up 420% year over year. Total Myriad Genetics earnings for the quarter were -$42.30 million. In the same quarter last year, Myriad Genetics's earnings per share (EPS) was -$0.10.

If you're new to stock investing, here's how to buy Myriad Genetics stock.

What was MYGN's earnings growth in the past year?

As of Q1 2023, Myriad Genetics's earnings has grown year over year. Myriad Genetics's earnings in the past year totalled -$112.00 million.

What is MYGN's earnings date?

Myriad Genetics's earnings date is Invalid Date. Add MYGN to your watchlist to be reminded of MYGN's next earnings announcement.

What was MYGN's revenue last quarter?

On Invalid Date, Myriad Genetics (NASDAQ: MYGN) reported Q4 2022 revenue of $177.80 million up 10.57% year over year. In the same quarter last year, Myriad Genetics's revenue was $160.80 million.

What was MYGN's revenue growth in the past year?

As of Q1 2023, Myriad Genetics's revenue has grown -1.77% year over year. This is 12.4 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 10.63%. Myriad Genetics's revenue in the past year totalled $678.40 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.